SavedAdd your journal

Journals / GORM:Gynecology Obstetrics & Reproductive Medicine / 2013 / Cilt: 19 - Sayı: 3

Ovaryen hiperstimülasyon sendromunun önlenmesinde gnrh antagonist ve coasting uygulamalarının karşılaştırılması

Coasting versus gnrh antagonist salvage for the prevention of ovarian hyperstimulation syndrome

HACER CAVİDAN GÜLERMAN
NAFİYE YILMAZ
Ayla ORUÇ SARGIN
Nazlı ÖZKAN
AYTEN TÜRKKANI
Esma SARIKAYA
Okan YENİCESU
Pages
176–179
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: Our results represent that both coasting and GnRH antagonist salvage are effective strategies to prevent OHSS in women undergoing long GnRH agonist IVF/ICSI cycles.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: The purpose of the present study is to compare the use of GnRH antagonist salvage ver- sus coasting for the prevention of OHSS in patients undergoing IVF/ICSI cycles with long GnRH agonist protocol.
📊
Key Findings & Data:STUDY DESIGN: Medical records of 91 patients (41 in coasting and 49 in GnRH antagonist group) iden- tified as at high risk of developing OHSS were reviewed retrospectively.
💡
Conclusion & Impact:CONCLUSION: Our results represent that both coasting and GnRH antagonist salvage are effective strategies to prevent OHSS in women undergoing long GnRH agonist IVF/ICSI cycles.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: The purpose of the present study is to compare the use of GnRH antagonist salvage ver- sus coasting for the prevention of OHSS in patients undergoing IVF/ICSI cycles with long GnRH agonist protocol. STUDY DESIGN: Medical records of 91 patients (41 in coasting and 49 in GnRH antagonist group) iden- tified as at high risk of developing OHSS were reviewed retrospectively. Groups were compared for oc- currence of moderate and severe OHSS, serum estradiol on the day of HCG and IVF outcomes. RESULTS: There were no differences between the groups in terms of moderate and severe OHSS and clinical pregnancy rates. Serum estradiol levels were decreased significantly in GnRH antagonist group. Quality of the transferred embryos was better in the coasting group. CONCLUSION: Our results represent that both coasting and GnRH antagonist salvage are effective strategies to prevent OHSS in women undergoing long GnRH agonist IVF/ICSI cycles.

Özet

AMAÇ: Çalışmanın amacı, uzun GnRH agonist protokol ile IVF-ICSI uygulaması yapılan hastalarda coasting ve GnRH an- tagonist uygulamalarının OHSS’u önlemede etkinliklerinin kar- şılaştırılmasıdır. GEREÇ VE YÖNTEM: OHSS gelişme riski yüksek olan 91 hastanın kayıtları retrospektif olarak incelenerek, coasting (n=41) ve antagonist (n=49) uygulanan hastalar, orta ve ciddi OHSS gelişimi, HCG günü estradiol düzeyleri ve IVF sonuçla- rı açısından karşılaştırıldı. BULGULAR: Orta şiddette ve ciddi OHSS gelişimi açısından gruplar arasında farklılık izlenmedi. HCG günü estradiol dü- zeyleri antagonist uygulanan grupta daha düşük bulundu, an- cak transfer edilen embriyoların kalitesinin coasting grubunda daha iyi olduğu gözlendi. Klinik gebelik oranları arasında fark yoktu. SONUÇ: Sonuçlarımız, coasting ve GnRH antagonist uygula- malarının her ikisinin de OHSS’yi önlemede etkili olduğunu göstermiştir.

🔖

Cite This Article

GÜLERMAN, H. C., YILMAZ, N., SARGIN, A. O., ÖZKAN, N., TÜRKKANI, A., SARIKAYA, E., YENİCESU, O. (2013). Ovaryen hiperstimülasyon sendromunun önlenmesinde gnrh antagonist ve coasting uygulamalarının karşılaştırılması. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 19 - Sayı: 3, 176–179. https://ajindex.com/articles/203642

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. International Committee for Monitoring Assisted Repro- ductive Technology, Adamson GD, de Mouzon J, Lan- caster P, Nygren KG, Sullivan E, Zegers-Hochschild F. World collaborative report on in vitro fertilization 2000. Fertil Steril 2006;85:1586-622
  2. Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73:883-96
  3. Brinsden PR, Wada I, Tan SL, Balen A, Jacobs HS. Diag- nosis, prevention and management of ovarian hyperstimu- lation syndrome. Br J Obstet Gynaecol 1995;102:767-72
  4. Mansour R, Aboulghar M, Serour G, Amin Y, Abou-Setta AM. Criteria of a successful coasting protocol for the pre- vention of severe ovarian hyperstimulation syndrome. Hum Reprod 2005;20:3167-72
  5. Abdallah R, Kligman I, Davis O, Rosenwaks Z. Withhol- ding gonadotropins until human chorionic gonadotropin administration. Semin Reprod Med 2010; 28:486-92 6. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559-77
  6. Aboulghar MA, Mansour RT, Amin YM, Al-Inany HG, Aboulghar MM, Serour GI. A prospective randomized study comparing coasting with GnRH antagonist adminis- tration in patients at risk for severe OHSS. Reprod Biomed Online 2007;15:271-9
  7. Gustofson RL, Segars JH, Larsen FW. Ganirelix acetate causes a rapid reduction in estradiol levels without ad- versely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyper- stimulation syndrome. Hum Reprod 2006;21:2830-7
  8. Hill MJ, Chason RJ, Payson MD, Segars JH, Csokmay JM. GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes. Reprod Biomed Online 2012;25:284-91
  9. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430-40
  10. Enskog A, Henriksson M, Unander M, Nilsson L, Brännström M. Prospective study of the clinical and labo- ratory parameters of patients in whom ovarian hyperstim- ulation syndrome developed during controlled ovarian hy- perstimulation for in vitro fertilization. Fertil Steril 1999; 71:808-14
  11. Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M, Limonta P. Luteinizing hormone-releasing hor- mone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 1996; 81:3930-7
  12. Leung PC, Cheng